109451
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
血清白细胞介素 - 1β 作为 ST 段抬高型心肌梗死患者行直接经皮冠状动脉介入治疗时无复流现象的新型预测指标
Authors Wang S, Wang H, Huang Y, Zhu J, Cheng Q, Gao C
Received 10 June 2025
Accepted for publication 8 October 2025
Published 31 October 2025 Volume 2025:18 Pages 15153—15164
DOI https://doi.org/10.2147/JIR.S545890
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Durga Prasanna Misra
Shengfang Wang,1– 3,* Hao Wang,4,* Yanqing Huang,5,* Jialu Zhu,1– 3 Qianqian Cheng,1– 3 Chuanyu Gao1– 3
1Department of Cardiology, Central China Fuwai Hospital of Zhengzhou University, Zhengzhou, People’s Republic of China; 2Department of Cardiology, Henan Provincial People’s Hospital Heart Center, Zhengzhou, People’s Republic of China; 3Henan Key Laboratory of Coronary Heart Disease Control & Prevention, Central China Fuwai Hospital, Zhengzhou, People’s Republic of China; 4Department of Cardiology, The Seventh People’s Hospital of Zhengzhou, Zhengzhou Cardiovascular Hospital, Zhengzhou, People’s Republic of China; 5Department of Histology and Embryology, Central South University, Changsha, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Chuanyu Gao, Email drgcy123456@163.com
Purpose: Despite primary percutaneous coronary intervention (PPCI), over 10% of ST-segment elevation myocardial infarction (STEMI) patients develop the no-reflow phenomenon, characterized by microvascular inflammation. Novel forms of cell death, such as pyroptosis (IL-1β/GSDMD/Caspase-1) and ferroptosis (ACSL4/GPX4/PTGS2), may contribute to this inflammation by promoting cytokine release and leukocyte recruitment. However, the biomarker potential of these pathways in predicting no-reflow remains unclear. This study aimed to evaluate whether serum levels of these proteins could predict no-reflow and improve risk stratification.
Patients and Methods: We enrolled 423 STEMI patients undergoing PPCI at two centers. No-reflow was defined as TIMI flow < 3 following PPCI, excluding mechanical obstruction. Serum levels of pyroptosis- (IL-1β, GSDMD, Caspase-1) and ferroptosis-related proteins (ACSL4, GPX4, PTGS2) were measured using ELISA. Multivariable logistic regression identified independent predictors. The baseline model included age, sex, cardiovascular risk factors, and other baseline differences. Biomarker performance was assessed using ROC analysis, net reclassification improvement (NRI), and integrated discrimination improvement (IDI).
Results: Of 423 patients, 81 (19.1%) developed no-reflow. The no-reflow group had significantly higher IL-1β [7.41 (5.55– 10.80) vs 4.91 (3.70– 6.71) pg/mL, P< 0.001] and GSDMD levels [2.34 (1.75– 3.48) vs 2.05 (1.64– 2.71) ng/mL, P=0.017]. IL-1β was an independent predictor of no-reflow in both continuous [per SD increase: adjusted OR=2.260, 95% CI 1.723– 2.966, P< 0.001] and categorical analyses [highest vs lowest tertile: OR=6.484, 95% CI 2.864– 14.679, P< 0.001]. ROC analysis showed IL-1β alone had an AUC of 0.745 (95% CI: 0.686– 0.804) for no-reflow prediction. Adding IL-1β to the baseline model improved discrimination (ΔAUC=0.091, P< 0.001; NRI=0.627, P< 0.001; IDI=0.109, P< 0.001).
Conclusion: Elevated serum IL-1β independently predicts no-reflow in STEMI patients, and its integration into the baseline model significantly enhances diagnostic performance, suggesting IL-1β as a potential therapeutic target.
Keywords: STEMI, no-reflow, inflammation, IL-1β, pyroptosis, ferroptosis
1Department of Cardiology, Central China Fuwai Hospital of Zhengzhou University, Zhengzhou, People’s Republic of China; 2Department of Cardiology, Henan Provincial People’s Hospital Heart Center, Zhengzhou, People’s Republic of China; 3Henan Key Laboratory of Coronary Heart Disease Control & Prevention, Central China Fuwai Hospital, Zhengzhou, People’s Republic of China; 4Department of Cardiology, The Seventh People’s Hospital of Zhengzhou, Zhengzhou Cardiovascular Hospital, Zhengzhou, People’s Republic of China; 5Department of Histology and Embryology, Central South University, Changsha, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Chuanyu Gao, Email drgcy123456@163.com
Purpose: Despite primary percutaneous coronary intervention (PPCI), over 10% of ST-segment elevation myocardial infarction (STEMI) patients develop the no-reflow phenomenon, characterized by microvascular inflammation. Novel forms of cell death, such as pyroptosis (IL-1β/GSDMD/Caspase-1) and ferroptosis (ACSL4/GPX4/PTGS2), may contribute to this inflammation by promoting cytokine release and leukocyte recruitment. However, the biomarker potential of these pathways in predicting no-reflow remains unclear. This study aimed to evaluate whether serum levels of these proteins could predict no-reflow and improve risk stratification.
Patients and Methods: We enrolled 423 STEMI patients undergoing PPCI at two centers. No-reflow was defined as TIMI flow < 3 following PPCI, excluding mechanical obstruction. Serum levels of pyroptosis- (IL-1β, GSDMD, Caspase-1) and ferroptosis-related proteins (ACSL4, GPX4, PTGS2) were measured using ELISA. Multivariable logistic regression identified independent predictors. The baseline model included age, sex, cardiovascular risk factors, and other baseline differences. Biomarker performance was assessed using ROC analysis, net reclassification improvement (NRI), and integrated discrimination improvement (IDI).
Results: Of 423 patients, 81 (19.1%) developed no-reflow. The no-reflow group had significantly higher IL-1β [7.41 (5.55– 10.80) vs 4.91 (3.70– 6.71) pg/mL, P< 0.001] and GSDMD levels [2.34 (1.75– 3.48) vs 2.05 (1.64– 2.71) ng/mL, P=0.017]. IL-1β was an independent predictor of no-reflow in both continuous [per SD increase: adjusted OR=2.260, 95% CI 1.723– 2.966, P< 0.001] and categorical analyses [highest vs lowest tertile: OR=6.484, 95% CI 2.864– 14.679, P< 0.001]. ROC analysis showed IL-1β alone had an AUC of 0.745 (95% CI: 0.686– 0.804) for no-reflow prediction. Adding IL-1β to the baseline model improved discrimination (ΔAUC=0.091, P< 0.001; NRI=0.627, P< 0.001; IDI=0.109, P< 0.001).
Conclusion: Elevated serum IL-1β independently predicts no-reflow in STEMI patients, and its integration into the baseline model significantly enhances diagnostic performance, suggesting IL-1β as a potential therapeutic target.
Keywords: STEMI, no-reflow, inflammation, IL-1β, pyroptosis, ferroptosis